PBM
TCRX icon

Propel Bio Management’s TScan Therapeutics TCRX Stock Holding History

Propel Bio Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,932,304
Closed -$3.52M – 24
2025
Q3 		$3.52M Sell
1,932,304
-154,835
-7% -$274K 3.52% 10
2025
Q2 		$3.03M Hold
2,087,139
– – 3.67% 9
2025
Q1 		$2.88M Hold
2,087,139
– – 3.35% 9
2024
Q4 		$6.34M Hold
2,087,139
– – 6.3% 7
2024
Q3 		$10.4M Hold
2,087,139
– – 6.03% 5
2024
Q2 		$12.2M Hold
2,087,139
– – 7.92% 3
2024
Q1 		$16.6M Hold
2,087,139
– – 9.65% 3
2023
Q4 		$12.2M Buy
+2,087,139
New +$9.55M 10.09% 3

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Propel Bio Management's TCRX Position: Q4 2025 in Review

Propel Bio Management sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 1,932,304 shares — an estimated $3.52M sold.

Propel Bio Management first reported a position in TCRX in Q4 2023 and held it in 8 quarters. The position peaked at $16.6M in Q1 2024. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Propel Bio Management reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Propel Bio Management sold 1,932,304 TScan Therapeutics shares in Q4 2025, an estimated $3.52M.
  • Propel Bio Management first reported a position in TScan Therapeutics in Q4 2023 and held it in 8 quarters.
  • Propel Bio Management's TScan Therapeutics position peaked at $16.6M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Propel Bio Management's 13F filing for Q4 2025, filed 11 Feb 2026.